Verdiva Bio
PrivateLast Round
Series A
Jan 9, 2025
Total Funding Raised
$411M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Verdiva Bio is a biopharmaceutical company that develops next-generation oral and injectable therapies for obesity, cardiometabolic disorders, and related complications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Verdiva Bio Comparables
Compare Verdiva Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pfizer | 85% | |
| Alveus Therapeutics | 82% | |
| Kailera Therapeutics | 81% |
Verdiva Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 9, 2025 |
Key People
Founding team and executive leadership
Verdiva Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A |
| RA Capital Management | Series A |
| Forbion | Series A |
| LYFE Capital | Series A |
| OrbiMed | Series A |
| Logos Capital | Series A |
| Lilly Asia Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 24, 2026
Grew 17% QoQ, from 64 to 75 employees.
- Apr 25, 2026
Grew 25% QoQ, from 59 to 74 employees.
Recent news
Latest coverage and updates
- hiresJul 23, 2026
Verdiva Bio Limited hired Jason Mallory as senior vice president of clinical development on Jul 23rd '26.
- is_developingJul 23, 2026
Verdiva Bio Limited is developing oral peptide therapies on Jul 23rd '26.
Verdiva Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Verdiva Bio's valuation, stock price, and market status.
Is Verdiva Bio a public or private company?
Verdiva Bio is a private company.
What is the current stock price of Verdiva Bio?
Verdiva Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Verdiva Bio worth (valuation)?
Valuation information for Verdiva Bio is not publicly available.
Can I buy Verdiva Bio stock?
Verdiva Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Verdiva Bio's last funding round?
Verdiva Bio's most recent funding round was Series A on January 9, 2025.
Who are the main investors in Verdiva Bio?
Key investors in Verdiva Bio include Forbion Capital Partners, General Atlantic.
Will Verdiva Bio IPO soon?
No public IPO plans have been announced for Verdiva Bio.
How can I track Verdiva Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Verdiva Bio's secondary market activity and sign up for updates.